Inovio Pharmaceuticals (NASDAQ:INO) Shares Down 5.2%

Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) were down 5.2% on Friday . The stock traded as low as $2.15 and last traded at $2.18, approximately 611,152 shares traded hands during trading. A decline of 44% from the average daily volume of 1,093,200 shares. The stock had previously closed at $2.30.

Several research analysts have recently weighed in on INO shares. Zacks Investment Research cut shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating and set a $3.50 price target on the stock. in a research report on Tuesday, May 28th. Piper Jaffray Companies decreased their target price on shares of Inovio Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 17th. ValuEngine raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. BidaskClub cut shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of Inovio Pharmaceuticals in a research report on Tuesday, June 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Inovio Pharmaceuticals currently has an average rating of “Buy” and an average price target of $7.35.

The stock’s 50-day simple moving average is $2.68 and its 200 day simple moving average is $3.29. The company has a quick ratio of 4.59, a current ratio of 4.59 and a debt-to-equity ratio of 1.49. The company has a market cap of $223.81 million, a price-to-earnings ratio of -2.08 and a beta of 2.03.



Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.02). The company had revenue of $0.14 million during the quarter, compared to analyst estimates of $4.69 million. Inovio Pharmaceuticals had a negative net margin of 1,560.70% and a negative return on equity of 142.10%. During the same period in the previous year, the company earned ($0.07) EPS. On average, sell-side analysts expect that Inovio Pharmaceuticals Inc will post -1.06 EPS for the current fiscal year.

In other news, Director David B. Weiner sold 16,352 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $2.72, for a total transaction of $44,477.44. Following the sale, the director now owns 797,110 shares of the company’s stock, valued at $2,168,139.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jong Joseph Kim sold 500,000 shares of the stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $2.44, for a total transaction of $1,220,000.00. Following the sale, the chief executive officer now directly owns 1,911,055 shares in the company, valued at approximately $4,662,974.20. The disclosure for this sale can be found here. Insiders have sold 2,645,905 shares of company stock worth $6,290,223 in the last three months. Corporate insiders own 7.90% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of Inovio Pharmaceuticals by 4.5% during the second quarter. BlackRock Inc. now owns 7,708,829 shares of the biopharmaceutical company’s stock worth $22,665,000 after purchasing an additional 335,356 shares in the last quarter. Wasatch Advisors Inc. increased its stake in shares of Inovio Pharmaceuticals by 15.2% during the second quarter. Wasatch Advisors Inc. now owns 6,735,726 shares of the biopharmaceutical company’s stock worth $19,803,000 after buying an additional 887,316 shares during the period. Nikko Asset Management Americas Inc. increased its stake in shares of Inovio Pharmaceuticals by 49.7% during the second quarter. Nikko Asset Management Americas Inc. now owns 4,884,100 shares of the biopharmaceutical company’s stock worth $14,359,000 after buying an additional 1,621,581 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Inovio Pharmaceuticals by 53.1% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,884,100 shares of the biopharmaceutical company’s stock worth $14,359,000 after buying an additional 1,694,891 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Inovio Pharmaceuticals by 0.7% during the second quarter. Vanguard Group Inc. now owns 4,860,200 shares of the biopharmaceutical company’s stock worth $14,289,000 after buying an additional 35,018 shares during the period. 50.91% of the stock is currently owned by institutional investors and hedge funds.

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Featured Story: What are benefits of a growth and income fund?

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.